Literature DB >> 15227742

Complete resolution of posttransplant lymphoproliferative disorder (diffuse large B-cell lymphoma) with reduction of immunosuppressive therapy.

Han Jak Ryu1, Jee Sook Hahn, Yu Seun Kim, Kiil Park, Woo Ick Yang, Jong Doo Lee.   

Abstract

Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplantation. PTLD is the disorder arising from the combined effects of Epstein-Barr virus associated lymphoid proliferation with the disruption of the normal immune control by the cytotoxic T cells. The treatment for PTLD is one of the most controversial topics in solid organ transplantation. It is well known that the initial management of PTLD is a reduction of immunosuppression. Early diagnosis and the early reduction in immunosuppression are essential even for monomorphic lymphoma. We report here on a case of the complete resolution of PTLD (diffuse large B cell lymphoma) which occurred after a drastic reduction of immunosuppression in a renal transplant recipient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15227742     DOI: 10.3349/ymj.2004.45.3.527

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  3 in total

1.  Post-transplant lymphoproliferative disorder localized in the colon after liver transplantation: report of a case.

Authors:  Min Jung Kim; Seong Hyeon Yun; Ho-Kyung Chun; Woo Yong Lee; Yong Beom Cho
Journal:  Surg Today       Date:  2009-12-08       Impact factor: 2.549

Review 2.  An unusual case of spontaneous remission of Hodgkin's disease after a single cycle of COPP-ABV chemotherapy followed by infectious complications.

Authors:  Seung Min Bang; June Won Cheong; Woo Ick Yang; Jee Sook Hahn
Journal:  Yonsei Med J       Date:  2005-06-30       Impact factor: 2.759

Review 3.  Management of children after renal transplantation: highlights for general pediatricians.

Authors:  Keith K Lau; Lucy Giglia; Howard Chan; Anthony K Chan
Journal:  Transl Pediatr       Date:  2012-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.